Keratosis pilaris-like eruption secondary to nilotinib in a child

Pediatr Dermatol. 2020 Sep;37(5):968-969. doi: 10.1111/pde.14267. Epub 2020 Jun 29.

Abstract

Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14-year-old patient being treated with nilotinib who developed a keratosis pilaris-like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.

Keywords: BCR-ABL-positive; chronic; leukemia; myelogenous; protein kinase inhibitors.

Publication types

  • Case Reports

MeSH terms

  • Abnormalities, Multiple*
  • Adolescent
  • Antineoplastic Agents
  • Darier Disease*
  • Eyebrows / abnormalities*
  • Fusion Proteins, bcr-abl
  • Humans
  • Protein Kinase Inhibitors / adverse effects
  • Pyrimidines / adverse effects

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Fusion Proteins, bcr-abl
  • nilotinib

Supplementary concepts

  • Burnett Schwartz Berberian syndrome